Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 2
2003 1
2008 1
2009 2
2010 2
2011 1
2013 1
2014 2
2015 4
2016 2
2017 5
2018 3
2019 5
2020 5
2021 7
2022 10
2023 11
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

62 results

Results by year

Filters applied: . Clear all
Page 1
Blinatumomab Added to Chemotherapy in Infant Lymphoblastic Leukemia.
van der Sluis IM, de Lorenzo P, Kotecha RS, Attarbaschi A, Escherich G, Nysom K, Stary J, Ferster A, Brethon B, Locatelli F, Schrappe M, Scholte-van Houtem PE, Valsecchi MG, Pieters R. van der Sluis IM, et al. Among authors: nysom k. N Engl J Med. 2023 Apr 27;388(17):1572-1581. doi: 10.1056/NEJMoa2214171. N Engl J Med. 2023. PMID: 37099340 Clinical Trial.
Efficacy and safety of larotrectinib in TRK fusion-positive primary central nervous system tumors.
Doz F, van Tilburg CM, Geoerger B, Højgaard M, Øra I, Boni V, Capra M, Chisholm J, Chung HC, DuBois SG, Gallego-Melcon S, Gerber NU, Goto H, Grilley-Olson JE, Hansford JR, Hong DS, Italiano A, Kang HJ, Nysom K, Thorwarth A, Stefanowicz J, Tahara M, Ziegler DS, Gavrilovic IT, Norenberg R, Dima L, De La Cuesta E, Laetsch TW, Drilon A, Perreault S. Doz F, et al. Among authors: nysom k. Neuro Oncol. 2022 Jun 1;24(6):997-1007. doi: 10.1093/neuonc/noab274. Neuro Oncol. 2022. PMID: 34850167 Free PMC article. Clinical Trial.
Sustained Survival Benefit in Recurrent Medulloblastoma by a Metronomic Antiangiogenic Regimen: A Nonrandomized Controlled Trial.
Peyrl A, Chocholous M, Sabel M, Lassaletta A, Sterba J, Leblond P, Nysom K, Torsvik I, Chi SN, Perwein T, Jones N, Holm S, Nyman P, Mörse H, Öberg A, Weiler-Wichtl L, Leiss U, Haberler C, Schmook MT, Mayr L, Dieckmann K, Kool M, Gojo J, Azizi AA, André N, Kieran M, Slavc I. Peyrl A, et al. Among authors: nysom k. JAMA Oncol. 2023 Dec 1;9(12):1688-1695. doi: 10.1001/jamaoncol.2023.4437. JAMA Oncol. 2023. PMID: 37883081 Free PMC article. Clinical Trial.
The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trial.
Kilburn LB, Khuong-Quang DA, Hansford JR, Landi D, van der Lugt J, Leary SES, Driever PH, Bailey S, Perreault S, McCowage G, Waanders AJ, Ziegler DS, Witt O, Baxter PA, Kang HJ, Hassall TE, Han JW, Hargrave D, Franson AT, Yalon Oren M, Toledano H, Larouche V, Kline C, Abdelbaki MS, Jabado N, Gottardo NG, Gerber NU, Whipple NS, Segal D, Chi SN, Oren L, Tan EEK, Mueller S, Cornelio I, McLeod L, Zhao X, Walter A, Da Costa D, Manley P, Blackman SC, Packer RJ, Nysom K. Kilburn LB, et al. Among authors: nysom k. Nat Med. 2024 Jan;30(1):207-217. doi: 10.1038/s41591-023-02668-y. Epub 2023 Nov 17. Nat Med. 2024. PMID: 37978284 Free PMC article. Clinical Trial.
[Cannabis is not for children or adolescents].
Opstrup P, Olsen M, Nysom K, Uldall PV, Walther-Larsen S. Opstrup P, et al. Among authors: nysom k. Ugeskr Laeger. 2017 Oct 16;179(42):V07170527. Ugeskr Laeger. 2017. PMID: 29053095 Free article. Review. Danish.
Paediatric Strategy Forum for medicinal product development of DNA damage response pathway inhibitors in children and adolescents with cancer: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration.
Pearson ADJ, Federico S, Gatz SA, Ortiz M, Lesa G, Scobie N, Gounaris I, Weiner SL, Weigel B, Unger TJ, Stewart E, Smith M, Slotkin EK, Reaman G, Pappo A, Nysom K, Norga K, McDonough J, Marshall LV, Ludwinski D, Ligas F, Karres D, Kool M, Horner TJ, Henssen A, Heenen D, Hawkins DS, Gore L, Bender JG, Galluzzo S, Fox E, de Rojas T, Davies BR, Chakrabarti J, Carmichael J, Bradford D, Blanc P, Bernardi R, Benchetrit S, Akindele K, Vassal G. Pearson ADJ, et al. Among authors: nysom k. Eur J Cancer. 2023 Sep;190:112950. doi: 10.1016/j.ejca.2023.112950. Epub 2023 Jun 21. Eur J Cancer. 2023. PMID: 37441939 Free article. Review.
AcSé-ESMART, a European precision cancer medicine proof-of-concept platform trial.
Geoerger B, Paoletti X, Bautista F, Gatz SA, Marshall LV, André N, Berlanga P, Ducassou S, Pasqualini C, Casanova M, Zwaan CM, Nysom K, Rubino J, Goff DV, Archambaud B, Abbou S, Schleiermacher G, Dufour C, Blanc P, Hoog-Labouret N, Buzyn A, Vassal G. Geoerger B, et al. Among authors: nysom k. Nat Med. 2023 Dec;29(12):2985-2987. doi: 10.1038/s41591-023-02580-5. Nat Med. 2023. PMID: 37857712 No abstract available.
Combination Early-Phase Trials of Anticancer Agents in Children and Adolescents.
Moreno L, DuBois SG, Glade Bender J, Mauguen A, Bird N, Buenger V, Casanova M, Doz F, Fox E, Gore L, Hawkins DS, Izraeli S, Jones DTW, Kearns PR, Molenaar JJ, Nysom K, Pfister S, Reaman G, Smith M, Weigel B, Vassal G, Zwaan CM, Paoletti X, Iasonos A, Pearson ADJ. Moreno L, et al. Among authors: nysom k. J Clin Oncol. 2023 Jun 20;41(18):3408-3422. doi: 10.1200/JCO.22.02430. Epub 2023 Apr 4. J Clin Oncol. 2023. PMID: 37015036 Free PMC article. Review.
Outpatient administration of naxitamab in combination with granulocyte-macrophage colony-stimulating factor in patients with refractory and/or relapsed high-risk neuroblastoma: Management of adverse events.
Mora J, Chan GC, Morgenstern DA, Nysom K, Bear MK, Tornøe K, Kushner BH. Mora J, et al. Among authors: nysom k. Cancer Rep (Hoboken). 2023 Jan;6(1):e1627. doi: 10.1002/cnr2.1627. Epub 2022 May 17. Cancer Rep (Hoboken). 2023. PMID: 35579862 Free PMC article. Review.
62 results